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Abstract
Introduction. Chronic post-anoxic myoclonus, also
known as Lance-Adams syndrome, may develop following
hypoxic brain injury, and is resistant to pharmacological
therapy. Case report. The patient we presented developed
post-anoxic action myoclonus with severe, completely in-
capacitating myoclonic jerks. Myoclonus did not respond
to the treatment with commonly used agents, i.e. valproate
and clonazepam alone or in combination. Improvement of
the action myoclonus was observed only after adding
levetiracetam.  Conclusion. Although Lance-Adams syn-
drome may not be fully curable at this point, levetiracetam
appears to be a promising agent that can significantly im-
prove functional level and overall quality of life of patients
with this disorder.
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Apstrakt
Uvod. Hroniÿni postanoksiÿni mioklonus, poznat i kao
Lance-Adamsov sindrom, može se javiti nakon hipoksiÿ-
ne povrede mozga i rezistentan je na farmakološku tera-
piju. Prikaz bolesnika. Prikazan je bolesnik sa postan-
kosiÿnim mioklonusom i izraženim miokloniÿnim trzaje-
vima koji su doveli do njegove potpune onesposobljeno-
sti. Mioklonije nisu reagovale na uobiÿajene lekove kao
što je valproat i klonazepam pojedinaÿno ili u kombina-
ciji. Poboljšanje akcionog mioklonusa postignuto je tek
nakon uvoĀenja levetiracetama u dodatnoj terapiji. Zak-
ljuÿak.  Iako još nije moguýe potpuno izleÿenje sindro-
ma Lans-Adams, levetiracetat znatno popravlja funkcio-
nalni i nivo ukupnog kvaliteta života bolesnika sa ovim
poremeýajem.
Kljuÿne reÿi:
mioklonus; anoksija; sindrom; dijagnoza; leÿenje
lekovima; lekovi rezistencija; leÿenje, ishod.
Introduction
Post-hypoxic action myoclonus (PAM), first described
by Lance and Adams in 1963, is characterized mainly by ac-
tion myoclonus and associated cerebellar ataxia, mild intel-
lectual deficit and resistance to conventional pharmacologi-
cal agents 
1.  This syndrome is caused by anoxia of the cen-
tral nervous system, generally in the course of primary respi-
ratory failure. It is a rare condition, with fewer than 150
cases reported in the literature. We presented a male patient
who survived hypoxic brain injury, after which he developed
severe action-triggered jerks unresponsive to standard anti-
convulsants, and had partial improvement only after leveti-
racetam was added. We discussed clinical and electroence-
pahalographic features of our patient in the light of the rele-
vant published data.
Case report
According to available medical history data, a 58-year-
old male injured in a car-accident (March 2009) experienced
anoxia during surgery on his fractured zygomatic bone in a lo-
cal hospital. For the following five days the patient remained
in coma, receiving respiratory support. While in coma, eight
hours after the surgery, the patient developed seizure-like gen-
eralized tonic-clonic movements. He was treated with pheno-
barbital and diazepam injections. Electroencephalography
(EEG) was not performed at this time, and brain computed
tomography (CT) was reported as normal.
After five days, when the patient regained conscious-
ness, he had no hemiparesis or aphasia, but generalized myo-
clonus was present accompanied by dysmetria, dysarthria
and impaired swallowing. Because of myoclonus he was un-Strana 516 VOJNOSANITETSKI PREGLED Volumen 71, Broj 5
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able to sit from a supine position, stand up after sitting in a
wheelchair, walk without aid, or perform simple, coordinated
manual tasks. Myoclonic jerks would disappear only during
sleep. Repeated brain CT showed abnormal, frontal and tem-
poral lesions corresponding to contusion.
Brain magnetic resonance imaging (MRI) and magnetic
resonance angiography (MRA) performed three weeks after
the anoxic event demonstrated a few lacunar infarcts in the
cerebral white matter without signs of postcontusion lesions,
and with insignificant bilateral stenosis of the common and
internal carotid arteries (Figure 1).
Despite the treatment with phenobarbital (100 mg/day
p.o.), diazepam (20 mg/day i.m.) and carbamazepine (300
mg/day p.o.) the patient continued to have multifocal myo-
clonus that increased with voluntary movements and nurse’s
manipulation. The patient was therefore referred to electro-
physiological evaluation at our tertiary clinic. Simple EEG
demonstrated paroxismal abnormalities in the form of rapid
series of spikes and polyspikes on slow-wave background
activity. The EEG spikes were highly frequent, generalized,
with an amplitude maximum at the vertex and often followed
by slow waves (Figure 2). Myoclonic jerks and paroxismal
EEG abnormalities were not strictly related to each other.
Somatosensory evoked responses (SSEP) were normal.
The diagnosis of post-hypoxic action myoclonus was
established, and discontinuation of phenobarbital and car-
bamazepine was advised. Drugs known to control myoclo-
nus were administered progressively, first sodium valproate
(VPA) (1000 mg/day p.o.) and then clonazepam (CZP) (2
mg/day p.o.), thereafter the frequency and severity of myo-
clonus slightly decreased. The patient’s speech and swal-
lowing improved, he was able to turn himself in bed, sit up
Fig. 1 – Lacunar infarcts in the cerebral white matter demonstrated by brain
magnetic resonance imaging (MRI); magnetic resonance angiography (MRA) without
significant pathological changes.
Fig. 2 –Electroencephalography (EEG) before levetiracetam (LEV) was added (longitudinal montage; 30 mm/sec, 7 ȝV/mm,
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and stand up for a while, but he was unable to walk without
aid.
At this point he was discharged from the local hospital
and for the following six months he was receiving VPA
(1750 mg/day), CZP (6 mg/day), lamotrigine (LTG) (200
mg/day) and sertraline (50 mg/day). However, there was no
further improvement, and due to action myoclonus the pa-
tient was bed-bound and completely dependent. Leveti-
racetam (LEV) (250 mg b.d.) was added to the therapy, to
which an immediate response was seen. The LEV dose was
gradually increased up to 3,000 mg/day and a marked clini-
cal improvement of action myoclonus was achieved. On
EEG, central spiking was dramatically reduced, small-
amplitude intermediate centro-temporal slow activity over
both hemispheres on normal background activity was noted
(Figure 3). The patient’s overall quality of life was consid-
erably improved. He could sit and stand up without support
and had no significant cognitive impairment. Dysarthria and
daily activities, such as eating and dressing, improved as
well. However, he was still mildly ataxic, able to walk only
about 150 meters independently, prone to sudden falling be-
cause of “sudden weakness in his legs” (negative myoclo-
nus), still requiring supervision.
The patient’s condition remained constant on the ther-
apy (VPA 1,500 mg/day + CZP 6 mg/day + LEV 3,000
mg/day) for the past two years.
Discussion
Post-anoxic action myoclonus is a distinct entity that
can develop in survivors of anoxic brain injury. It is a rare
but devastating complication of near-fatal cardiopulmonary
arrest (e.g., cardiac arrest, anesthesia accident during surgical
procedures, asthmatic attacks, airway obstruction and drug
intoxication).
Clinical presentation of PAM is quite distinct and in
most cases, like in our case, the diagnosis can be established
on the clinical ground alone. In chronic PAM, myoclonus is
noted within a few days to some months after the acute epi-
sode. The myoclonus may be accompanied by dysmetria,
dysarthria and ataxia, with relatively preserved higher cogni-
tive functions 
2, 3. Several types of myoclonus can be ob-
served in this syndrome: cortical, subcortical, brainstem, re-
ticular myoclonus, and exaggerated startle. Myoclonus may
originate from either cortical or subcortical foci, although
both forms may coexist 
4. Myoclonus may be focal, multifo-
cal, segmental or generalized, it may be spontaneous or
stimulus-sensitive, but typically is precipitated by movement
intention and voluntary action 
2. Both positive and negative
myoclonus may exist, separately or in association. Negative
myoclonus may involve the hamstrings and quadriceps mus-
cles, producing a characteristic “bouncing” gait and/or sud-
den falls 
5, 6. Lapses of postural control due to negative myo-
clonus may play an important role in producing the clinical
picture of more obvious muscle jerking 
7. Clinical course of
chronic PAM is variable. Gradually, myoclonus and neuro-
logical deficits improve, although the brainstem reticular re-
flex myoclonus may be associated with a poorer prognosis 
2,
5. In our patient, myoclonus was multifocal, action- and
stimulus-sensitive, bilateral and generalized. Action jerks
were more prominent distally and occurred particularly at the
onset of a limb movement. His facial muscles were involved
as well, affecting speech and swallowing. He was mildly
ataxic without cognitive impairment.  As it is typical with
negative myoclonus, in our patient lapses in contraction of
anti-gravity muscles became more apparent when the patient
attempted to walk. The mechanism underlying this
movement disorder remains largely unknown. Alterations in
multiple neurochemical systems have been reported in ani-
mal and human studies, pointing out that abnormalities
Fig. 3 – Electroencephalography (EEG) after levetiracetam (LEV) was added (longitudinal montage; 30 mm/sec, 7 ȝV/mm,
70.0 Hz, 1,600 Hz, 50Hz).Strana 518 VOJNOSANITETSKI PREGLED Volumen 71, Broj 5
Božiý K, et al. Vojnosanit Pregl 2014; 71(5): 515–519.
within the serotonin system and/or a loss of GABA-ergic in-
hibition may influence the pathophysiological mechanism of
PAM
 8, 9. According to recent neuroimaging data, it is likely
that subcortical neuronal networks including the ventrolateral
thalamus are involved 
10, 11.
Imaging findings of brain CT and MRI in patients with
PAM are usually unremarkable. MRI may occasionally show
loss of grey-white matter distinction and selective neuronal
injuries in the grey deep nuclei, but usually it is not specific
of PAM 
2, 5. In agreement with published data, in our patient
brain MRI revealed only a few small lesions in the cerebral
white matter consistent with infarction.
In chronic PAM EEG background activity is usually
normal, occasionally associated with spikes or spike-waves
that are enhanced by movement or other stimuli 
2, 12. In some
cases, EEG-EMG polygraphy with back-averaging and giant
somatosensory evoked potentials are required to confirm the
diagnosis (i. e., cortical origin of action myoclonus). In our
patient, the standard EEG was initially abnormal. Abnor-
malities consisted of bilateral spikes, sharp waves or
spike/poly-spike slow-wave complexes mainly over the ver-
tex on slow (theta/alpha) background activity. These were
only occasionally accompanied by muscle jerks. Cortical
somatosensory evoked potentials (SSEPs) were normal. The
EEG-EMG polygraphy with back-averaging of the EEG ac-
tivity preceding jerks were not done.
Therapy of chronic PAM is difficult and empiric. Be-
cause of the relative rarity of the syndrome, case-controlled
data are lacking. Several treatment options have been previ-
ously proposed, however, the results are inconsistent. Drugs
that augment GABA-ergic transmission are useful in all
types of myoclonus, and CZP and VPA are the first-line
treatments 
13, 14. Approximately 50% of patients respond to
treatment, although often partially 
5. Standard anticonvul-
sants, such as phenobarbital, carbamazepine and lamotrigine,
were not efficient in our patient, which is in accordance with
previous findings 
15. Efficacy of piracetam, as a very potent
antimyoclonic agent, was reported many years ago, first in
patients with Lance-Adams syndrome 
16. However, very high
doses of piracetam (20–45 g/day) needed to reach efficacy is
not very practical and can impede compliance 
17–19.
Novel anti-epileptic medications such as levetiracetam
and zonisamide (ZNS) have recently been described to be
useful in the control of myoclonus disorders, including
Lance-Adams syndrome 
20, 21. A body of evidence suggests
that LEV may be effective in both positive and negative
myoclonus 
22, 23 as well as in patients with post-hypoxic and
postencephalitic myoclonus 
24. The exact mechanism of
action of LEV is unknown. It was found to be effective for
the treatment of PAM in higher doses (3000–4000 mg/day)
than those used for seizures 
25, 26, although Krauss et al. 
24
achieved a good response with low doses (1000 mg/day). In
our patient improvement of action myoclonus ensued in the
first day of LEV therapy. We used relatively high doses of
LEV add-on therapy (3000 mg/day) and successfully con-
trolled the action myoclonus without any unwanted side ef-
fects. Interestingly, LEV was not so effective for negative
myoclonus in our case. However, although our patient did
not recover completely, the treatment with LEV add-on
therapy seems to have significantly improved his quality of
life.
Conclusion
Although Lance-Adams syndrome may not be fully
curable at this point, levetiracetam appears to be a promising
agent that can significantly improve functional level and
overall quality of life of patients with this disorder.
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